Case Studies

Too busy for a healthy lifestyle?

As active contributors in research, sometimes it’s nice to take a step back and reflect how our work evolves from novel treatment to everyday practice.

Read More

January 7th, 2014

Strong evidence for use of dual antiplatelet therapy in ‘mini-strokes’

Evidence is increasing of the benefits, without increased risks, of using dual antiplatelet therapy – aspirin and clopidogrel – as soon as possible and continued for up to 3-months in patients with minor acute ischaemic stroke or transient ischaemic stroke (TIA), so-called mini-strokes. The evidence is derived from multiple randomised controlled trials, including a recent […]

Read More

September 19th, 2013

Benefits of DPPIV-inhibitors still uncertain

The recent SAVOR-TIMI 53 (saxagliptin) and EXAMINE (alogliptin) trials recently reported the effects of the DPPIV inhibitor class of glucose lowering agents in people with diabetes. As required by the US FDA, both drugs were found not to increase cardiovascular risk, allowing the agents to be registered for use in that country. Good news, it would […]

Read More

September 17th, 2013

New treatment for the most serious form of stroke

Intracerebral hemorrhage is the most serious form of stroke with high rates of mortality and a low chance of recovery to functional independence. In Asia Pacific, it affects more than one million people annually, kills one third of them and leaves most survivors with disability. For reasons yet unknown, intracerebral hemorrhage is also more prevalent […]

Read More

August 6th, 2013

COPD and its co-morbidities

COPD is one of the world’s leading cause of death with prevalence ranging from 6% to 19% globally. This disease is particularly relevant for us in Asia Pacific as risk factors such as smoking, biomass fuels, TB and air pollution are more prevalent than other regions. For example COPD prevalence in Chinese males is estimated […]

Read More

August 6th, 2013

Developing clinical trials to meet the demands of 21st century diseases

Diseases that dominate the 21st century need a 21st century approach in the way we design and conduct clinical trials. To meet this need, George Clinical is primarily focused on large-scale studies with high-impact outcomes, particularly where smaller pre-registration trials need to be expanded to larger populations. George Clinical has been managing clinical trials in […]

Read More

February 11th, 2013

The true cost of cancer in South East Asia

Cancer is well established as a major leading cause of death across the world. Perhaps what is less known is that 70% of these deaths occur in low and middle-income countries, with Asia absorbing most of the impact. In 2002, 3.5 million people died of cancer in Asia. This is expected to increase to 8.1 […]

Read More

September 19th, 2012

Intensive blood pressure lowering reduces heart attacks

One quarter of the world’s adult population suffers from hypertension, and although it has no obvious symptoms, it can lead to heart attacks, stroke, kidney failure and blindness. Despite this, there has been great uncertainty as to how intensively blood pressure should be lowered to obtain maximal benefit and minimize risks. Researchers from Australia, China, […]

Read More

September 3rd, 2012
George Clinical

1-901-259-0888

Profits from George Clinical support the work of The George Institute for Global Health.

Join our Mailing List

Add George Clinical to your network